Skip to main content

Latest updates from major conferences

Edited by:
Delong Liu: New York Medical College, USA
Kongming Wu: Tongji Medical College of Huazhong University of Science and Technology, China

Submission Status: Open   |   Submission Deadline: Ongoing 


 Journal of Hematology & Oncology and Experimental Hematology & Oncology are calling for submissions to our Collection on "Latest updates from major conferences." This cross-journal series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders.

Submit to collection

Journal of Hematology & Oncology 

Experimental Hematology & Oncology 

About the collection

Journal of Hematology & Oncology and Experimental Hematology & Oncology are calling for submissions to our Collection on "Latest updates from major conferences." This cross-journal series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference.

Each Correspondence should start with “To the editor," include two tables, and fewer than 700 words in the text. It should also have two subsections to better delineate the content. There should be fewer than 12 references. 

Image credit: © PR. H. PIGUET / CNRI /  Science Photo Library

  1. Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an incr...

    Authors: Wenjie Zhang, Sumei Li, Jinlan Long, Shufeng Xie, Minghui Wang, Han Liu and Zhenshu Xu
    Citation: Experimental Hematology & Oncology 2024 13:43
    Content type: Correspondence Published on:

  2. Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer...

    Authors: Junli Lu, Yiming Luo, Dean Rao, Tiantian Wang, Zhen Lei, Xiaoping Chen, Bixiang Zhang, Yiwei Li, Bifeng Liu, Limin Xia and Wenjie Huang
    Citation: Experimental Hematology & Oncology 2024 13:39
    Content type: Review Published on:

  3. Protein degraders, emerging as a novel class of therapeutic agents, have gained widespread attention due to their advantages. They have several advantages over traditional small molecule inhibitors, including ...

    Authors: Guangcai Zhong, Ran Kong, Shi Feng, Cong Wang, Qingbo Hao, Weilin Xie and Xiangxiang Zhou
    Citation: Journal of Hematology & Oncology 2024 17:14
    Content type: Correspondence Published on:

  4. Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of a...

    Authors: Jingyi Yang, Hao Guo, Lu Han, Yongping Song and Keshu Zhou
    Citation: Experimental Hematology & Oncology 2024 13:25
    Content type: Correspondence Published on:

  5. Transcription factor GATA1 controls the delicate balance between proliferation, differentiation and apoptosis in both the erythroid and megakaryocytic lineages. In addition to full-length GATA1, there is an GA...

    Authors: Daishi Ishihara, Atsushi Hasegawa, Ikuo Hirano, James Douglas Engel, Masayuki Yamamoto and Ritsuko Shimizu
    Citation: Experimental Hematology & Oncology 2024 13:24
    Content type: Correspondence Published on:

  6. Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venet...

    Authors: Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2024 13:17
    Content type: Correspondence Published on:

  7. The 2022 European LeukemiaNet (ELN) updated the previous risk classification published in 2017 but the prognostic significance for allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear...

    Authors: Haixiao Zhang, Xinhui Zheng, Wenwen Guo, Yonghui Xia, Rongli Zhang, Weihua Zhai, Xin Chen, Qiaoling Ma, Donglin Yang, Jialin Wei, Aiming Pang, Yi He, Sizhou Feng, Jianxiang Wang, Mingzhe Han and Erlie Jiang
    Citation: Experimental Hematology & Oncology 2024 13:16
    Content type: Correspondence Published on:

  8. Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight ...

    Authors: Qian Qin, Hollie Sheffield, Sean M. Taasan, Andrew Z. Wang and Tian Zhang
    Citation: Journal of Hematology & Oncology 2023 16:112
    Content type: Editorial Published on:

  9. Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immuno...

    Authors: Matthieu Roulleaux-Dugage and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2023 16:93
    Content type: Editorial Published on:

  10. Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy...

    Authors: Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo and Yongping Song
    Citation: Journal of Hematology & Oncology 2023 16:92
    Content type: Correspondence Published on:

  11. Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to...

    Authors: Xinyuan Liu, Juanjuan Zhao, Xiangqian Guo and Yongping Song
    Citation: Journal of Hematology & Oncology 2023 16:90
    Content type: Correspondence Published on:

  12. Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Onco...

    Authors: Yuanhong Jiang, Siyu Wu, Rong Li, Jiazheng Yu, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Zhenqun Xu, Shijie Li and Xiaonan Chen
    Citation: Experimental Hematology & Oncology 2023 12:68
    Content type: Correspondence Published on:

  13. Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approva...

    Authors: James F. Wu and Binod Dhakal
    Citation: Journal of Hematology & Oncology 2023 16:86
    Content type: Correspondence Published on:

  14. Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the ...

    Authors: Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li and Xiaonan Chen
    Citation: Journal of Hematology & Oncology 2023 16:85
    Content type: Correspondence Published on:

  17. Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), w...

    Authors: Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2023 12:57
    Content type: Correspondence Published on:

  19. B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue att...

    Authors: Jieyun Xia, Zhenyu Li and Kailin Xu
    Citation: Journal of Hematology & Oncology 2023 16:60
    Content type: Correspondence Published on:

  20. Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhib...

    Authors: Andrew Wang, James Liu and Jeffrey J. Pu
    Citation: Journal of Hematology & Oncology 2023 16:53
    Content type: Correspondence Published on:

  21. Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously unt...

    Authors: Zhijuan Lin, Long Liu, Zhifeng Li and Bing Xu
    Citation: Experimental Hematology & Oncology 2023 12:41
    Content type: Correspondence Published on:

  25. Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented...

    Authors: Katherine W. DiNardo, Thomas W. LeBlanc and Hui Chen
    Citation: Journal of Hematology & Oncology 2023 16:17
    Content type: Correspondence Published on:

Submission Guidelines

Back to top

For both journals, the submission guidelines and links to submit are available here:

During the submission process you will be asked whether you are submitting to a Collection, please select "Latest updates from major conferences" from the dropdown menu.

Articles will undergo the journal's standard peer-review process: Journal of Hematology & Oncology  and Experimental Hematology & Oncology and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published. The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.